Maria Isabel Fiel

Maria Isabel Fiel

Auto-generated profile, based on publicly available information

Maria Isabel Fiel

Department of Pathology, Molecular and Cell‐Based Medicine Icahn School of Medicine at Mount Sinai New York New York USA

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2024 in Hepatology
Verified
Journal Article
Closed access
RSRichard K. Sterling
Richard K. Sterling
ADAndres Duarte-Rojo
Andres Duarte-Rojo
KPKeyur Patel
Keyur Patel
SASumeet K. Asrani
Sumeet K. Asrani
MAMouaz Alsawas
Mouaz Alsawas
DRDon C. Rockey
Don C. Rockey
An abstract is unavailable. This article is available as a PDF only.

4 January 2023 in Science Translational Medicine
Verified
Journal Article
Closed access
SWShuang Wang
Shuang Wang
KLKenneth Li
Kenneth Li
EPEliana Pickholz
Eliana Pickholz
RDRoss Dobie
Ross Dobie
KMKylie P. Matchett
Kylie P. Matchett
SFScott Laurence Friedman
Scott Laurence Friedman
Advanced hepatic fibrosis, driven by the activation of hepatic stellate cells (HSCs), affects millions worldwide and is the strongest predictor of mortality in nonalcoholic steatohepatitis (NASH); however, there are no approved antifibrotic therapies. To identify antifibrotic drug targets, we integrated progressive transcriptomic and morphological responses that accompany HSC activation in advanced disease using single-nucleus RNA sequencing and tissue clearing in a robust murine NASH model. In advanced fibrosis, we found that an autocrine HSC signaling circuit emerged that was composed of 68 receptor-ligand interactions conserved between murine and human NASH. These predicted interactions were supported by the parallel appearance of markedly increased direct stellate cell-cell contacts in murine NASH. As proof of principle, pharmacological inhibition of one such autocrine interaction, neurotrophic receptor tyrosine kinase 3–neurotrophin 3, inhibited human HSC activation in culture and reversed advanced murine NASH fibrosis. In summary, we uncovered a repertoire of antifibrotic drug targets underlying advanced fibrosis in vivo. The findings suggest a therapeutic paradigm in which stage-specific therapies could yield enhanced antifibrotic efficacy in patients with advanced hepatic fibrosis.

1 July 2015 in Journal of Hepatology
Verified
Journal Article
Open access
PKPeri Kocabayoglu
Peri Kocabayoglu
ALAbigale Lade
Abigale Lade
YLYoungmin A. Lee
Youngmin A. Lee
ADAna-Cristina Dragomir
Ana-Cristina Dragomir
XSXiaochen Sun
Xiaochen Sun
SFScott Laurence Friedman
Scott Laurence Friedman
Rapid induction of β-PDGF receptor (β-PDGFR) is a core feature of hepatic stellate cell activation, but its cellular impact in vivo is not well characterized. We explored the contribution of β-PDGFR-mediated pathway activation to hepatic stellate cell responses in liver injury, fibrogenesis, and carcinogenesis in vivo using genetic models with divergent β-PDGFR activity, and assessed its prognostic implications in human cirrhosis. The impact of either loss or constitutive activation of β-PDGFR in stellate cells on fibrosis was assessed following carbon tetrachloride (CCl4) or bile duct ligation. Hepatocarcinogenesis in fibrotic liver was tracked after a single dose of diethylnitrosamine (DEN) followed by repeated injections of CCl4. Genome-wide expression profiling was performed from isolated stellate cells that expressed or lacked β-PDGFR to determine deregulated pathways and evaluate their association with prognostic gene signatures in human cirrhosis. Depletion of β-PDGFR in hepatic stellate cells decreased injury and fibrosis in vivo, while its auto-activation accelerated fibrosis. However, there was no difference in development of DEN-induced pre-neoplastic foci. Genomic profiling revealed ERK, AKT, and NF-κB pathways and a subset of a previously identified 186-gene prognostic signature in hepatitis C virus (HCV)-related cirrhosis as downstream of β-PDGFR in stellate cells. In the human cohort, the β-PDGFR signature was not associated with HCC development, but was significantly associated with a poorer outcome in HCV cirrhosis. β-PDGFR is a key mediator of hepatic injury and fibrogenesis in vivo and contributes to the poor prognosis of human cirrhosis, but not by increasing HCC development.

15 March 2024 in Hepatology
Verified
Journal Article
Closed access
RSRichard K. Sterling
Richard K. Sterling
KPKeyur Patel
Keyur Patel
ADAndres Duarte-Rojo
Andres Duarte-Rojo
SASumeet K. Asrani
Sumeet K. Asrani
MAMouaz Alsawas
Mouaz Alsawas
DRDon C. Rockey
Don C. Rockey
An abstract is unavailable. This article is available as a PDF only.

22 June 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
NFNaoto Fujiwara
Naoto Fujiwara
NKNaoto Kubota
Naoto Kubota
ECEmilie Crouchet
Emilie Crouchet
BKBhuvaneswari Koneru
Bhuvaneswari Koneru
CMCesia A. Marquez
Cesia A. Marquez
YHYujin Hoshida
Yujin Hoshida
Prediction of hepatocellular carcinoma (HCC) risk is an urgent unmet need in patients with nonalcoholic fatty liver disease (NAFLD). In cohorts of 409 patients with NAFLD from multiple global regions, we defined and validated hepatic transcriptome and serum secretome signatures predictive of long-term HCC risk in patients with NAFLD. A 133-gene signature, prognostic liver signature (PLS)–NAFLD, predicted incident HCC over up to 15 years of longitudinal observation. High-risk PLS-NAFLD was associated with IDO1 + dendritic cells and dysfunctional CD8 + T cells in fibrotic portal tracts along with impaired metabolic regulators. PLS-NAFLD was validated in independent cohorts of patients with NAFLD who were HCC naïve (HCC incidence rates at 15 years were 22.7 and 0% in high- and low-risk patients, respectively) or HCC experienced (de novo HCC recurrence rates at 5 years were 71.8 and 42.9% in high- and low-risk patients, respectively). PLS-NAFLD was bioinformatically translated into a four-protein secretome signature, PLSec-NAFLD, which was validated in an independent cohort of HCC-naïve patients with NAFLD and cirrhosis (HCC incidence rates at 15 years were 37.6 and 0% in high- and low-risk patients, respectively). Combination of PLSec-NAFLD with our previously defined etiology-agnostic PLSec-AFP yielded improved HCC risk stratification. PLS-NAFLD was modified by bariatric surgery, lipophilic statin, and IDO1 inhibitor, suggesting that the signature can be used for drug discovery and as a surrogate end point in HCC chemoprevention clinical trials. Collectively, PLS/PLSec-NAFLD may enable NAFLD-specific HCC risk prediction and facilitate clinical translation of NAFLD-directed HCC chemoprevention.

28 May 2008 in Liver Transplantation
Verified
Journal Article
Open access
PDF file
MFM. Isabel Fiel
M. Isabel Fiel
KAKaushik Agarwal
Kaushik Agarwal
CSCarmen Stanca
Carmen Stanca
NENassim Elhajj
Nassim Elhajj
NKNikolas Kontorinis
Nikolas Kontorinis
TSThomas D. Schiano
Thomas D. Schiano
De novo autoimmune hepatitis has been described in both pediatric and adult liver transplantation (LT) recipients. Studies of small numbers of patients have proposed it to be an alloimmune hepatitis or form of chronic rejection. We have recently noted an increasing number of patients with post-LT recurrent hepatitis C virus (HCV) developing this, with an apparent negative impact on outcome and survival. We term this entity posttransplant plasma cell hepatitis (PCH). A search of our institution's pathology database was performed with the terms “plasma cell(s),” “lymphoplasmacytic infiltrate,” and “liver allograft.” A histological scoring system was devised to more reliably diagnose PCH in the setting of recurrent HCV. Thirty-eight patients were identified, and their clinical data were analyzed. Sixty percent had a negative outcome as defined by the development of cirrhosis, need for retransplantation, or death. Eighty-two percent had recent lowering of immunosuppression or subtherapeutic calcineurin inhibitor levels; 58% developed PCH within 2 years post-LT. Histologic resolution of PCH was associated with good outcome (P < 0.001). Patients not receiving treatment had a negative outcome (P = 0.007) as did patients receiving corticosteroids as therapy (P = 0.02). Persistence (P = 0.007) or recurrence of PCH was associated with negative outcome. In conclusion, PCH is a histologic variant of rejection. On liver biopsy, PCH can at times be difficult to diagnose, and the use of a standardized scoring system is recommended to differentiate it from other forms of allograft dysfunction. Treatment by optimization of immunosuppression without the use of corticosteroids appears effective. The development of PCH in the setting of recurrent HCV is a negative prognostic factor for patient outcome and allograft failure. Liver Transpl 14:861–871, 2008. © 2008 AASLD.